IQVIA Holdings Inc. $IQV Stock: WASHINGTON TRUST Co Boosts Holdings

WASHINGTON TRUST Co boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 90,286 shares of the medical research company’s stock after acquiring an additional 2,308 shares during the quarter. WASHINGTON TRUST Co owned 0.05% of IQVIA worth $24,273,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in IQV. Financial Freedom LLC bought a new position in shares of IQVIA during the first quarter valued at $25,000. Ascentis Independent Advisors acquired a new stake in IQVIA in the first quarter valued at $25,000. Compass Financial Management LLC acquired a new stake in IQVIA in the second quarter valued at $27,000. Elevation Wealth Partners LLC raised its position in IQVIA by 218.8% during the 2nd quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company’s stock worth $30,000 after purchasing an additional 105 shares during the last quarter. Finally, Pension & Wealth Management Advisors Inc. bought a new position in IQVIA during the 3rd quarter worth $30,000. 89.62% of the stock is owned by institutional investors.

Insider Transactions at IQVIA

In other news, insider James G. Berkshire sold 2,668 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the transaction, the insider owned 10,890 shares of the company’s stock, valued at $2,845,883.70. This represents a 19.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider W. Richard Staub sold 5,500 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the sale, the insider owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 15,581 shares of company stock valued at $3,796,021. 1.70% of the stock is owned by insiders.

IQVIA Trading Up 0.4%

NYSE IQV traded up $1.15 during trading hours on Friday, hitting $279.47. 981,209 shares of the company’s stock were exchanged, compared to its average volume of 1,322,001. The firm has a market cap of $46.00 billion, a price-to-earnings ratio of 34.67, a PEG ratio of 2.45 and a beta of 1.17. The stock has a 50-day simple moving average of $263.98 and a 200 day simple moving average of $216.43. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $282.98.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. IQVIA’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts forecast that IQVIA Holdings Inc. will post 11.54 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the company. BMO Capital Markets lifted their target price on IQVIA from $270.00 to $305.00 in a report on Monday, October 19th. Robert W. Baird increased their price target on IQVIA from $287.00 to $324.00 and gave the company an “outperform” rating in a research note on Tuesday, September 29th. Weiss Ratings upgraded IQVIA from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, September 24th. Truist Financial reaffirmed a “buy” rating and issued a $329.00 price objective (up from $300.00) on shares of IQVIA in a research note on Monday, September 28th. Finally, HSBC upped their target price on IQVIA from $280.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, September 1st. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $278.75.

About IQVIA

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.